CA2021489C - Methods and compositions for chromosome-specific staining - Google Patents

Methods and compositions for chromosome-specific staining Download PDF

Info

Publication number: CA2021489C
Authority: CA; Canada
Prior art keywords: nucleic acid; sequences; hybridization; probe; chromosome
Prior art date: 1989-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2021489

Other languages

English (en)

French (fr)

Other versions

CA2021489A1 (en

Inventor

Joe W. Gray

Daniel Pinkel

Douglas Tkachuk

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

University of California San Diego UCSD

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-19

Filing date

1990-07-18

Publication date

2004-01-27

1990-07-18 Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD

1990-07-18 Priority to CA002449414A priority Critical patent/CA2449414A1/en

1991-01-20 Publication of CA2021489A1 publication Critical patent/CA2021489A1/en

2004-01-27 Application granted granted Critical

2004-01-27 Publication of CA2021489C publication Critical patent/CA2021489C/en

2010-07-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000000349 chromosome Anatomy 0.000 title claims abstract description 410
238000000034 method Methods 0.000 title claims abstract description 302
238000010186 staining Methods 0.000 title claims abstract description 154
239000000203 mixture Substances 0.000 title abstract description 65
239000000523 sample Substances 0.000 claims abstract description 420
108020004414 DNA Proteins 0.000 claims abstract description 266
150000007523 nucleic acids Chemical group 0.000 claims abstract description 160
230000002759 chromosomal effect Effects 0.000 claims abstract description 99
230000002068 genetic effect Effects 0.000 claims abstract description 98
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims abstract description 94
230000008707 rearrangement Effects 0.000 claims abstract description 91
230000031864 metaphase Effects 0.000 claims abstract description 79
239000000463 material Substances 0.000 claims abstract description 71
108020004711 Nucleic Acid Probes Proteins 0.000 claims abstract description 63
238000004458 analytical method Methods 0.000 claims abstract description 63
239000002853 nucleic acid probe Substances 0.000 claims abstract description 63
238000001514 detection method Methods 0.000 claims abstract description 55
230000016507 interphase Effects 0.000 claims abstract description 55
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 47
238000007901 in situ hybridization Methods 0.000 claims abstract description 34
230000002559 cytogenic effect Effects 0.000 claims abstract description 33
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
238000009396 hybridization Methods 0.000 claims description 268
210000004027 cell Anatomy 0.000 claims description 157
230000003252 repetitive effect Effects 0.000 claims description 120
239000012634 fragment Substances 0.000 claims description 105
241000282414 Homo sapiens Species 0.000 claims description 87
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 78
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 69
102000039446 nucleic acids Human genes 0.000 claims description 55
108020004707 nucleic acids Proteins 0.000 claims description 55
210000004940 nucleus Anatomy 0.000 claims description 48
230000000295 complement effect Effects 0.000 claims description 44
230000001605 fetal effect Effects 0.000 claims description 41
239000012128 staining reagent Substances 0.000 claims description 38
230000008569 process Effects 0.000 claims description 37
230000000903 blocking effect Effects 0.000 claims description 36
238000003752 polymerase chain reaction Methods 0.000 claims description 36
239000008241 heterogeneous mixture Substances 0.000 claims description 35
230000005945 translocation Effects 0.000 claims description 35
239000013598 vector Substances 0.000 claims description 33
108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims description 28
238000002372 labelling Methods 0.000 claims description 27
239000013612 plasmid Substances 0.000 claims description 25
230000008774 maternal effect Effects 0.000 claims description 24
208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 23
208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 23
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 23
102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 21
102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims description 21
210000004369 blood Anatomy 0.000 claims description 21
239000008280 blood Substances 0.000 claims description 21
101000783817 Agaricus bisporus lectin Proteins 0.000 claims description 20
101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 claims description 20
101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 20
210000001106 artificial yeast chromosome Anatomy 0.000 claims description 19
230000004927 fusion Effects 0.000 claims description 19
238000010367 cloning Methods 0.000 claims description 17
239000013611 chromosomal DNA Substances 0.000 claims description 16
238000012217 deletion Methods 0.000 claims description 16
230000037430 deletion Effects 0.000 claims description 16
210000004754 hybrid cell Anatomy 0.000 claims description 15
230000003321 amplification Effects 0.000 claims description 14
238000003199 nucleic acid amplification method Methods 0.000 claims description 14
210000002993 trophoblast Anatomy 0.000 claims description 13
238000005406 washing Methods 0.000 claims description 10
238000000684 flow cytometry Methods 0.000 claims description 9
238000000386 microscopy Methods 0.000 claims description 9
125000003729 nucleotide group Chemical group 0.000 claims description 9
238000003780 insertion Methods 0.000 claims description 8
230000037431 insertion Effects 0.000 claims description 8
238000005259 measurement Methods 0.000 claims description 8
239000002773 nucleotide Substances 0.000 claims description 8
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 7
229910052588 hydroxylapatite Inorganic materials 0.000 claims description 7
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 7
238000012216 screening Methods 0.000 claims description 7
238000012800 visualization Methods 0.000 claims description 7
238000002105 Southern blotting Methods 0.000 claims description 6
210000000265 leukocyte Anatomy 0.000 claims description 6
230000005855 radiation Effects 0.000 claims description 5
108700025690 abl Genes Proteins 0.000 claims description 4
238000011065 in-situ storage Methods 0.000 claims description 4
230000000644 propagated effect Effects 0.000 claims description 4
230000002285 radioactive effect Effects 0.000 claims description 4
238000012360 testing method Methods 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
230000002255 enzymatic effect Effects 0.000 claims description 3
238000012544 monitoring process Methods 0.000 claims description 3
238000009609 prenatal screening Methods 0.000 claims description 3
241001515965 unidentified phage Species 0.000 claims description 3
238000002512 chemotherapy Methods 0.000 claims description 2
239000003446 ligand Substances 0.000 claims description 2
230000003211 malignant effect Effects 0.000 claims description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical group [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
229910052753 mercury Inorganic materials 0.000 claims description 2
238000004393 prognosis Methods 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
238000002054 transplantation Methods 0.000 claims description 2
208000034951 Genetic Translocation Diseases 0.000 claims 1
238000000149 argon plasma sintering Methods 0.000 claims 1
238000004587 chromatography analysis Methods 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 28
201000010099 disease Diseases 0.000 abstract description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
238000011160 research Methods 0.000 abstract description 13
201000011510 cancer Diseases 0.000 abstract description 9
238000004980 dosimetry Methods 0.000 abstract description 8
238000003149 assay kit Methods 0.000 abstract description 3
230000004069 differentiation Effects 0.000 abstract description 2
108090000623 proteins and genes Proteins 0.000 description 37
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 32
230000027455 binding Effects 0.000 description 31
230000004075 alteration Effects 0.000 description 30
210000003917 human chromosome Anatomy 0.000 description 30
239000000872 buffer Substances 0.000 description 26
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 25
101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 25
102100026008 Breakpoint cluster region protein Human genes 0.000 description 24
230000005856 abnormality Effects 0.000 description 23
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 20
238000011534 incubation Methods 0.000 description 20
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 20
239000011616 biotin Substances 0.000 description 17
229960002685 biotin Drugs 0.000 description 17
239000000243 solution Substances 0.000 description 17
208000031404 Chromosome Aberrations Diseases 0.000 description 16
230000002159 abnormal effect Effects 0.000 description 16
235000020958 biotin Nutrition 0.000 description 16
210000002230 centromere Anatomy 0.000 description 15
239000003086 colorant Substances 0.000 description 15
108091008146 restriction endonucleases Proteins 0.000 description 15
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
102000053602 DNA Human genes 0.000 description 13
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 13
239000000126 substance Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
108060002716 Exonuclease Proteins 0.000 description 12
108091081062 Repeated sequence (DNA) Proteins 0.000 description 12
102000013165 exonuclease Human genes 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
238000002955 isolation Methods 0.000 description 11
239000010410 layer Substances 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
208000011580 syndromic disease Diseases 0.000 description 11
238000011282 treatment Methods 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
238000010276 construction Methods 0.000 description 10
230000029087 digestion Effects 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
239000011734 sodium Substances 0.000 description 10
238000010561 standard procedure Methods 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
108090001008 Avidin Proteins 0.000 description 9
241000283707 Capra Species 0.000 description 9
206010008805 Chromosomal abnormalities Diseases 0.000 description 9
201000010374 Down Syndrome Diseases 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000007792 addition Methods 0.000 description 9
239000002243 precursor Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
108020004682 Single-Stranded DNA Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
238000009826 distribution Methods 0.000 description 8
108010011505 fluorescein-avidin Proteins 0.000 description 8
238000013507 mapping Methods 0.000 description 8
210000004214 philadelphia chromosome Anatomy 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
101150049556 Bcr gene Proteins 0.000 description 7
108010067770 Endopeptidase K Proteins 0.000 description 7
108700024394 Exon Proteins 0.000 description 7
102000006382 Ribonucleases Human genes 0.000 description 7
108010083644 Ribonucleases Proteins 0.000 description 7
238000012512 characterization method Methods 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
108010052305 exodeoxyribonuclease III Proteins 0.000 description 7
239000008267 milk Substances 0.000 description 7
235000013336 milk Nutrition 0.000 description 7
210000004080 milk Anatomy 0.000 description 7
230000009871 nonspecific binding Effects 0.000 description 7
238000013519 translation Methods 0.000 description 7
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
150000001540 azides Chemical class 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
238000012552 review Methods 0.000 description 6
238000000926 separation method Methods 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
239000000725 suspension Substances 0.000 description 6
230000014616 translation Effects 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000004568 cement Substances 0.000 description 5
230000002380 cytological effect Effects 0.000 description 5
230000009977 dual effect Effects 0.000 description 5
229920001971 elastomer Polymers 0.000 description 5
230000007613 environmental effect Effects 0.000 description 5
235000013861 fat-free Nutrition 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
231100000722 genetic damage Toxicity 0.000 description 5
238000010353 genetic engineering Methods 0.000 description 5
239000011521 glass Substances 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000010191 image analysis Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
241000894007 species Species 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
108091060290 Chromatid Proteins 0.000 description 4
239000003298 DNA probe Substances 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
241000701959 Escherichia virus Lambda Species 0.000 description 4
208000026350 Inborn Genetic disease Diseases 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
210000004756 chromatid Anatomy 0.000 description 4
231100000005 chromosome aberration Toxicity 0.000 description 4
239000000470 constituent Substances 0.000 description 4
238000004925 denaturation Methods 0.000 description 4
230000036425 denaturation Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
229960000633 dextran sulfate Drugs 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
208000016361 genetic disease Diseases 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
-1 nucleoside triphosphate Chemical class 0.000 description 4
238000010422 painting Methods 0.000 description 4
238000003793 prenatal diagnosis Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
210000001082 somatic cell Anatomy 0.000 description 4
108091035539 telomere Proteins 0.000 description 4
210000003411 telomere Anatomy 0.000 description 4
102000055501 telomere Human genes 0.000 description 4
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
101150033421 ABL gene Proteins 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
230000004544 DNA amplification Effects 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
201000009928 Patau syndrome Diseases 0.000 description 3
239000004365 Protease Substances 0.000 description 3
201000000582 Retinoblastoma Diseases 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
208000037280 Trisomy Diseases 0.000 description 3
206010044686 Trisomy 13 Diseases 0.000 description 3
208000006284 Trisomy 13 Syndrome Diseases 0.000 description 3
208000026928 Turner syndrome Diseases 0.000 description 3
230000001594 aberrant effect Effects 0.000 description 3
ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
208000036878 aneuploidy Diseases 0.000 description 3
231100001075 aneuploidy Toxicity 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
210000003855 cell nucleus Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
210000004252 chorionic villi Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003280 clastogen Substances 0.000 description 3
239000013599 cloning vector Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 3
229910000397 disodium phosphate Inorganic materials 0.000 description 3
239000000975 dye Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000000799 fluorescence microscopy Methods 0.000 description 3
238000010448 genetic screening Methods 0.000 description 3
210000004090 human X chromosome Anatomy 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
230000004807 localization Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000011278 mitosis Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
230000003169 placental effect Effects 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
206010053884 trisomy 18 Diseases 0.000 description 3
CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108091023043 Alu Element Proteins 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
208000037088 Chromosome Breakage Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
240000006497 Dianthus caryophyllus Species 0.000 description 2
235000009355 Dianthus caryophyllus Nutrition 0.000 description 2
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
102000025850 HLA-A2 Antigen Human genes 0.000 description 2
108010074032 HLA-A2 Antigen Proteins 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
101000962529 Mesobuthus martensii Hyaluronidase-1 Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
241001494479 Pecora Species 0.000 description 2
201000010769 Prader-Willi syndrome Diseases 0.000 description 2
241000288906 Primates Species 0.000 description 2
102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 2
108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 2
108020004518 RNA Probes Proteins 0.000 description 2
239000003391 RNA probe Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010044688 Trisomy 21 Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
238000002669 amniocentesis Methods 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
230000008711 chromosomal rearrangement Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000003748 differential diagnosis Methods 0.000 description 2
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
230000005284 excitation Effects 0.000 description 2
238000005562 fading Methods 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
108010081400 fluorescein isothiocyante avidin Proteins 0.000 description 2
239000000499 gel Substances 0.000 description 2
229940094991 herring sperm dna Drugs 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000005865 ionizing radiation Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000000415 mammalian chromosome Anatomy 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000007431 microscopic evaluation Methods 0.000 description 2
230000000394 mitotic effect Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
230000001902 propagating effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000000527 sonication Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000001360 synchronised effect Effects 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 1
BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
VHONNXFZCAICNI-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=CC=C2N1 VHONNXFZCAICNI-UHFFFAOYSA-N 0.000 description 1
101150106774 9 gene Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000576133 Alphasatellites Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010011385 Cri-du-chat syndrome Diseases 0.000 description 1
101000851141 Crotalus molossus nigrescens Snake venom metalloproteinase Proteins 0.000 description 1
206010067477 Cytogenetic abnormality Diseases 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010061819 Disease recurrence Diseases 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000702224 Enterobacteria phage M13 Species 0.000 description 1
208000001951 Fetal Death Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
206010055690 Foetal death Diseases 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000011786 HLA-A Antigens Human genes 0.000 description 1
108010075704 HLA-A Antigens Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000907951 Homo sapiens Chymotrypsin-like elastase family member 3B Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000220645 Leonotis nepetifolia Species 0.000 description 1
208000001804 Monosomy 5p Diseases 0.000 description 1
208000002693 Multiple Abnormalities Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
101710086015 RNA ligase Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241001415395 Spea Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
101710098624 Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
210000002593 Y chromosome Anatomy 0.000 description 1
AZRNEVJSOSKAOC-VPHBQDTQSA-N [[(2r,3s,5r)-5-[5-[(e)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]prop-1-enyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCCNC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)=C1 AZRNEVJSOSKAOC-VPHBQDTQSA-N 0.000 description 1
231100000071 abnormal chromosome number Toxicity 0.000 description 1
ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical compound N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
238000007630 basic procedure Methods 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
244000309466 calf Species 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000002962 chemical mutagen Substances 0.000 description 1
ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
230000005886 chromosome breakage Effects 0.000 description 1
230000011855 chromosome organization Effects 0.000 description 1
210000001726 chromosome structure Anatomy 0.000 description 1
231100000506 clastogen Toxicity 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
239000012954 diazonium Substances 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
231100000479 fetal death Toxicity 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000834 fixative Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000002440 industrial waste Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229960000901 mepacrine Drugs 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000001531 micro-dissection Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000026211 mitotic metaphase Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000004091 panning Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008775 paternal effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
238000011309 routine diagnosis Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000010187 selection method Methods 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
231100000378 teratogenic Toxicity 0.000 description 1
230000003390 teratogenic effect Effects 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA 2021489 1989-07-19 1990-07-18 Methods and compositions for chromosome-specific staining Expired - Lifetime CA2021489C (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002449414A CA2449414A1 (en)	1989-07-19	1990-07-18	Methods and compositions for chromosome specific staining

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US38209489A	1989-07-19	1989-07-19
US382,094		1989-07-19
US44466989A	1989-12-01	1989-12-01
US444,669		1989-12-01
US49709890A	1990-03-20	1990-03-20
US497,098		1990-03-20

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002449414A Division CA2449414A1 (en)	1989-07-19	1990-07-18	Methods and compositions for chromosome specific staining

Publications (2)

Publication Number	Publication Date
CA2021489A1 CA2021489A1 (en)	1991-01-20
CA2021489C true CA2021489C (en)	2004-01-27

Family

ID=27409560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2021489 Expired - Lifetime CA2021489C (en)	1989-07-19	1990-07-18	Methods and compositions for chromosome-specific staining

Country Status (3)

Country	Link
CA (1)	CA2021489C (he)
IL (1)	IL94906A (he)
PT (1)	PT94751A (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5512433A (en) *	1990-11-08	1996-04-30	Vysis, Inc.	Methods and compounds for labeling DNA with xanthine and lower alkyl substituted xanthine derivatives and reagents for the in situ detection of chromosomes
CA2060267A1 (en) *	1991-02-22	1992-08-23	Joe W. Gray	Chromosome specific staining to detect genetic rearrangements
US6025126A (en)	1991-10-28	2000-02-15	Arch Development Corporation	Methods and compositions for the detection of chromosomal aberrations
US5976790A (en)	1992-03-04	1999-11-02	The Regents Of The University Of California	Comparative Genomic Hybridization (CGH)
US5698686A (en) *	1994-10-20	1997-12-16	Arch Development Corporation	Yeast telomerase compositions
CN112680442B (zh) *	2021-02-03	2024-03-08	河南省农业科学院	一种花生野生种基因组特异探针和使用方法

1990
- 1990-06-28 IL IL9490690A patent/IL94906A/he active IP Right Grant
- 1990-07-18 PT PT9475190A patent/PT94751A/pt not_active Application Discontinuation
- 1990-07-18 CA CA 2021489 patent/CA2021489C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PT94751A (pt)	1991-03-20
IL94906A (he)	1995-10-31
CA2021489A1 (en)	1991-01-20

Legal Events

Date	Code	Title	Description
1991-08-29	EEER	Examination request
2010-07-18	MKEX	Expiry

Publication	Publication Date	Title
EP0885971B1 (en)	2007-07-04	Methods and compositions for chromosome-specific staining
US8415464B2 (en)	2013-04-09	Chromosome-specific staining to detect genetic rearrangements
US5756696A (en)	1998-05-26	Compositions for chromosome-specific staining
US6596479B1 (en)	2003-07-22	Methods and compositions for chromosome-specific staining
US6344315B1 (en)	2002-02-05	Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
US5856089A (en)	1999-01-05	Method for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
WO1994028178A1 (en)	1994-12-08	In-situ hybridization probes for identification and banding of specific human chromosomes and regions
US6475720B1 (en)	2002-11-05	Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
USRE40929E1 (en)	2009-10-06	Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
EP0500290A2 (en)	1992-08-26	Chromosome-specific staining to detect genetic rearrangements
US20040235039A1 (en)	2004-11-25	Chromosome-specific staining to detect genetic rearrangements
CA2021489C (en)	2004-01-27	Methods and compositions for chromosome-specific staining
US8592155B2 (en)	2013-11-26	Method of detecting genetic deletions identified with chromosomal abnormalities
US6872817B1 (en)	2005-03-29	Method of staining target interphase chromosomal DNA
WO1992010566A1 (en)	1992-06-25	In-situ hybridization probes for identification and banding of specific human chromosomes and regions
NZ245427A (en)	1994-07-26	Methods and compositions for chromosome-specific staining
CA2449414A1 (en)	1991-01-20	Methods and compositions for chromosome specific staining
CA1301605C (en)	1992-05-26	Methods and compositions for chromosome specific staining
Gray et al.	1998	Compositions for chromosome-specific staining
Gray et al.	2008	Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17